Nextcure Inc (NXTC)
$1.62
Insights on Nextcure Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 68.7%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 312.3%
Performance
- $1.54$1.69$1.62
4.94%
Downside
Day's Volatility :8.61%
Upside
3.86%
- $0.98$2.57$1.62
39.51%
Downside
52 Weeks Volatility :61.87%
Upside
36.96%
Returns
| Period | Nextcure Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 9.87% | 0.0% |
6 Months | 33.6% | 0.0% |
1 Year | -10.22% | 0.0% |
3 Years | -80.0% | -20.1% |
Highlights
Market Capitalization | 45.6M |
Book Value | $4.1 |
Earnings Per Share (EPS) | -2.25 |
Wall Street Target Price | 5.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -27.08% |
Return On Equity TTM | -44.49% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -54.2M |
EBITDA | -64.0M |
Diluted Eps TTM | -2.25 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.74 |
EPS Estimate Next Year | -1.78 |
EPS Estimate Current Quarter | -0.46 |
EPS Estimate Next Quarter | -0.41 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 208.64%
Technicals Summary
Sell
Neutral
Buy
Nextcure Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Nextcure Inc | 3.73% | 33.6% | -10.22% | -80.0% | -91.6% |
 Moderna, Inc. | 37.56% | 83.82% | 13.37% | -12.47% | 553.14% |
 Regeneron Pharmaceuticals, Inc. | 10.42% | 24.29% | 32.26% | 98.6% | 210.52% |
 Novo Nordisk A/s | 7.9% | 30.89% | 58.53% | 230.87% | 458.51% |
 Vertex Pharmaceuticals Incorporated | 10.52% | 25.13% | 30.01% | 109.26% | 156.43% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Nextcure Inc | NA | NA | NA | -1.74 | -0.44 | -0.27 | NA | 4.1 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.46 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 29.16 | 29.16 | 1.46 | 44.2 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 45.83 | 45.83 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 28.9 | 28.9 | 0.53 | 17.11 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Nextcure Inc | Buy | $45.6M | -91.6% | NA | 0.0% |
Moderna, Inc. | Buy | $54.0B | 553.14% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.8B | 210.52% | 29.16 | 29.45% |
Novo Nordisk A/s | Buy | $592.1B | 458.51% | 45.83 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $115.1B | 156.43% | 28.9 | 39.46% |
Institutional Holdings
Orbimed Advisors, LLC
9.69%Sofinnova Ventures
9.55%Logos Global Management LP
6.88%Millennium Management LLC
4.05%Vanguard Group Inc
3.53%BlackRock Inc
3.18%
Company Information
nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col
Organization | Nextcure Inc |
Employees | 82 |
CEO | Mr. Michael S. Richman MSBA |
Industry | Biotechnology |
Discover More
A Spac I Acquisition Corp
$1.62
-2.99%
Keyarch Acquisition Corp
$1.62
-2.99%
Connexa Sports Technologies Inc
$1.62
-2.99%
Us Value Etf
$1.62
-2.99%
First Wave Biopharma Inc
$1.62
-2.99%
Global X Msci Next Emerging
$1.62
-2.99%
Fat Projects Acquisition Corp
$1.62
-2.99%
Ishares Intl Div Growth Etf
$1.62
-2.99%
Corsair Gaming, Inc.
$1.62
-2.99%